Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Expected to Earn Q2 2021 Earnings of ($0.79) Per Share

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Investment analysts at Wedbush reduced their Q2 2021 EPS estimates for shares of Y-mAbs Therapeutics in a research report issued to clients and investors on Wednesday, April 21st. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.79) per share for the quarter, down from their prior forecast of ($0.75). Wedbush currently has a “Outperform” rating and a $52.00 target price on the stock. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q3 2021 earnings at ($0.78) EPS, Q4 2021 earnings at ($0.77) EPS, FY2021 earnings at ($1.82) EPS, Q1 2022 earnings at ($0.71) EPS, Q3 2022 earnings at ($0.66) EPS, Q4 2022 earnings at ($0.65) EPS, FY2022 earnings at ($1.36) EPS, FY2023 earnings at ($2.04) EPS and FY2024 earnings at $0.38 EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Thursday, February 25th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.85) by $0.36. The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $4.18 million.

A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Y-mAbs Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 24th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $52.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, March 29th. HC Wainwright increased their price target on shares of Y-mAbs Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 8th. Finally, Bank of America downgraded shares of Y-mAbs Therapeutics from a “buy” rating to a “neutral” rating and set a $56.00 price target on the stock. in a research report on Friday, January 15th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $54.38.

Shares of YMAB opened at $27.04 on Friday. The stock has a market cap of $1.18 billion, a PE ratio of -9.10 and a beta of 1.36. Y-mAbs Therapeutics has a fifty-two week low of $24.77 and a fifty-two week high of $55.22. The firm’s 50-day simple moving average is $31.23 and its two-hundred day simple moving average is $42.29.

In other news, insider Thomas Gad sold 7,000 shares of the firm’s stock in a transaction on Monday, April 12th. The shares were sold at an average price of $26.61, for a total transaction of $186,270.00. Following the sale, the insider now directly owns 7,000 shares in the company, valued at approximately $186,270. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 38.40% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of YMAB. Artisan Partners Limited Partnership grew its stake in shares of Y-mAbs Therapeutics by 44.3% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,047,416 shares of the company’s stock worth $51,858,000 after buying an additional 321,788 shares in the last quarter. Ashford Capital Management Inc. purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth about $10,863,000. BlackRock Inc. lifted its holdings in Y-mAbs Therapeutics by 3.1% during the 4th quarter. BlackRock Inc. now owns 2,418,580 shares of the company’s stock valued at $119,744,000 after buying an additional 72,823 shares in the last quarter. Morgan Stanley lifted its holdings in Y-mAbs Therapeutics by 75.5% during the 4th quarter. Morgan Stanley now owns 132,285 shares of the company’s stock valued at $6,550,000 after buying an additional 56,893 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in Y-mAbs Therapeutics by 5.3% during the 4th quarter. Alliancebernstein L.P. now owns 1,010,319 shares of the company’s stock valued at $50,021,000 after buying an additional 50,803 shares in the last quarter. 53.20% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Recommended Story: What is the Difference Between Common Shares and Convertible Shares?

Earnings History and Estimates for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.